Business Wire

Xylem Clocks 113,000 Volunteer Hours in 2021, Doubling Time Donated to Help Tackle Water Challenges in 55 Countries

Share

Global water technology company, Xylem (NYSE:XYL), announced today that almost 80 percent of its 16,000 employees volunteered their time to help solve urgent water challenges in 2021. Xylem’s global team collectively donated 113,000 hours in their communities, across 55 countries.

The commitment of volunteer hours doubled from 2020 to 2021, despite the challenges of COVID-19. Xylem employees stepped up both in person, in their own communities, and virtually, finding new ways to make a difference. Initiatives included cleaning up waterways, supporting disaster response teams, and providing water education.

"Volunteering is one way we invest in our mission to solve the world’s biggest water challenges,” said Austin Alexander, Vice President of Sustainability and Social Impact at Xylem. “Our colleagues, customers and NGO partners showed real passion, last year – doubling the number of hours they volunteered, compared with 2020. It was particularly encouraging to see this uplift in the face of COVID-19. They found so many creative ways to help communities become more resilient – mentoring young people online, championing the efforts of our NGO partners, and supporting humanitarian relief efforts. It’s just so inspiring to see the impact they’ve had.”

Xylem’s volunteering initiatives are part of its corporate social responsibility program, Xylem Watermark. Xylem provides 10 hours of time off annually for employees to volunteer, with some of the volunteers’ efforts also contributing to Xylem’s 2025 Sustainability Goals, which include: providing access to clean water and sanitation for at least 20 million people living at the base of the global economic pyramid; providing water and WASH (Water and Sanitation Hygiene) education for 15 million people; and giving 1% company profits to water-related causes and education around the world.

In 2021, Xylem Watermark volunteering included:

  • Xylem China’s team supported communities in Henan and Shanxi Province affected by record-breaking floods, which affected millions of people and left many without access to safe or clean drinking water. The team set up a 24-hour contact center to support affected customers and assisted in the donation of pumps across the province to help discharge floodwater. In addition, Xylem’s China team donated food and water to the affected communities.
  • Xylem employees joined relief efforts in western Germany last summer, when almost a quarter of people living on the River Ahr experienced severe flooding, and more than 3,000 homes and businesses were destroyed. Xylem employees took part in clean-up efforts, raised funds to support the evacuation of affected families, and distributed food and hygiene kits to emergency shelters.
  • Over 800 Xylem employees, customers and community members participated in “Aquaton,” a month-long mileage challenge which raised funds for clean water access projects spanning seven countries in Latin America.
  • A diverse team of colleagues from South Africa, Europe and North America donated their engineering skills to support the work of Engineers Without Borders, rehabilitating WASH facilities at rural health clinics in Malawi.

About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our more than 16,000 diverse employees delivered revenue of $4.88 billion in 2020. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.

About Xylem Watermark
Xylem Watermark, the Company’s corporate citizenship program, was initiated in 2008, with a focus on protecting and providing safe water resources around the world and also educating people on water-related issues. The global initiative, which encompasses employee and stakeholder engagement, provides access to clean drinking water and sanitation, and humanitarian emergency response to help communities become more water-secure and sustainable.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Houston Spencer, Xylem
+1.914.240.3046
Houston.Spencer@xylem.com

Gill Curran, Edelman
+(353) 87 176 8124
Gill.Curran@edelman.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting27.5.2022 15:00:00 CEST | Press release

LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract Number:e16102 Abstract Title:Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis. The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses [1]. Approximately 50% of the advanced GC patients will develop p

FEELM unveils the world's first ceramic coil disposable pod solution at Vaper Expo UK 202227.5.2022 13:38:00 CEST | Press release

FEELM, the flagship atomization tech brand belonging to SMOORE, today showcased the world's first ceramic coil disposable pod solution series, FEELM Max at Vaper Expo UK 2022 in Birmingham, UK. By launching the solution and showcasing its cutting-edge ceramic coil heating technology, FEELM is introducing ceramic coil to the emerging category of disposable vape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005197/en/ (Photo: Business Wire) As a new category in the ascendant, the disposable vape has been growing in popularity since 2020. The market size of disposable (closed system) vaping product has grown to approximately USD2.125 billion in 2021, accounting for 22.7% of global vaping device market share; and it is expected to increase at a GAGR of over 28% from 2022 to 2026, being the fastest-growing category among all vaping products, according to the estimates of Frost & Suvillian. In 2022, the market size of disp

Mavenir’s Containerized Open vRAN Small Cell Solution Wins Award for Outstanding Contribution to Emerging Technology or Architecture27.5.2022 09:00:00 CEST | Press release

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced to have won the SCF Small Cell Awards 2022 for Outstanding Contribution to Emerging Technology or Architecture, for its design and delivery of the first fully containerized small cell Open Virtualized Radio Access Network (Open vRAN), for indoor and outdoor connectivity. Mavenir’s containerized Open vRAN solution is a first of its kind and combines the interoperability of Open RAN with the portability and flexibility of containers. This small cell solution brings the same future-forward approaches of Open RAN and containerization having significant impacts in macro networks to small cell networks. The deployment of a containerized solution is a significant milestone in the evolution of connectivity, moving away from the physical infrastructure to a digital cloud-based environment. Containers take virtualizati

TYAN Brings Modern HPC Server Platforms for Data Centers at ISC 202227.5.2022 09:00:00 CEST | Press release

TYAN®, an industry-leading server platform design manufacturer and MiTAC Computing Technology Corporation subsidiary, will exhibit its latest HPC platforms powered by 3rd Gen AMD EPYC™ Processors with AMD 3D V-Cache™ technology for data centers deployments at the ISC 2022 event from May 30th to June 1st at booth #D400. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005002/en/ TYAN’s Server Platforms Powered by AMD EPYC 7003 Series Processors Provide the Best Foundation for Data Centers that Can be Tailored to Specific Workloads (Photo: Business Wire) “The amount of data generated by humans and machines has increased exponentially and this requires a steady increase of data center compute performance, therefore, modern data centers need balanced hardware to efficiently manage growing data volumes,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's Server Infrastructure Business Unit. “TYAN’s ser

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination